Perioperative tumour marker levels as prognostic factors for surgical treatment of breast cancer liver metastases

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F18%3A10376166" target="_blank" >RIV/00216208:11140/18:10376166 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00669806:_____/18:10376166

Výsledek na webu

<a href="https://doi.org/10.21873/anticanres.12640" target="_blank" >https://doi.org/10.21873/anticanres.12640</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.21873/anticanres.12640" target="_blank" >10.21873/anticanres.12640</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Perioperative tumour marker levels as prognostic factors for surgical treatment of breast cancer liver metastases

Popis výsledku v původním jazyce

Breast cancer represents the most frequent cancer worldwide among women and i some of the most frequent causes of death in this population. Breast cancer liver metastases in most women are associated with concurrent BC dissemination to the lungs and bones and these represent the only site of metastatic BC in 12-15% women. Surgical Treatment of BCLM is an importatnt component of multimodal therapeutic approaches. In our view, one strategy that might improve the results of surgical management of BCLM is the search for early indicators of tumour dissemination or for prognostically high-risk patients. The tumour markers are general indicators used in monitoring and follow-up of patients. The aim of our retrospective study was to determine whether perioperative levels of clinically routinely used tumour markers influence overal survival (OS) and recurrence-free survival (RFS) of patients undergoing resection or thermoablative therapy for BCLM as part of a multimodal approach.

Název v anglickém jazyce

Perioperative tumour marker levels as prognostic factors for surgical treatment of breast cancer liver metastases

Popis výsledku anglicky

Breast cancer represents the most frequent cancer worldwide among women and i some of the most frequent causes of death in this population. Breast cancer liver metastases in most women are associated with concurrent BC dissemination to the lungs and bones and these represent the only site of metastatic BC in 12-15% women. Surgical Treatment of BCLM is an importatnt component of multimodal therapeutic approaches. In our view, one strategy that might improve the results of surgical management of BCLM is the search for early indicators of tumour dissemination or for prognostically high-risk patients. The tumour markers are general indicators used in monitoring and follow-up of patients. The aim of our retrospective study was to determine whether perioperative levels of clinically routinely used tumour markers influence overal survival (OS) and recurrence-free survival (RFS) of patients undergoing resection or thermoablative therapy for BCLM as part of a multimodal approach.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30212 - Surgery

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Anticancer Research

ISSN

0250-7005

e-ISSN

—

Svazek periodika

38

Číslo periodika v rámci svazku

6

Stát vydavatele periodika

GR - Řecká republika

Počet stran výsledku

6

Strana od-do

3647-3652

Kód UT WoS článku

000449934200055

EID výsledku v databázi Scopus

2-s2.0-85048210519